Peter T. Cangany, Jr. Purchases 75,000 Shares of Beneficient (NASDAQ:BENF) Stock

Beneficient (NASDAQ:BENFGet Free Report) Director Peter T. Cangany, Jr. acquired 75,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $0.93 per share, with a total value of $69,750.00. Following the acquisition, the director now owns 300,000 shares of the company’s stock, valued at $279,000. This trade represents a 33.33 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Beneficient Stock Up 8.8 %

Beneficient stock opened at $0.90 on Friday. The company has a fifty day moving average price of $1.27 and a two-hundred day moving average price of $2.43. Beneficient has a 12 month low of $0.72 and a 12 month high of $51.14.

Hedge Funds Weigh In On Beneficient

A hedge fund recently raised its stake in Beneficient stock. Stifel Financial Corp boosted its holdings in Beneficient (NASDAQ:BENFFree Report) by 138.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,300 shares of the company’s stock after purchasing an additional 14,100 shares during the quarter. Stifel Financial Corp owned approximately 0.57% of Beneficient worth $30,000 at the end of the most recent quarter. 90.57% of the stock is owned by institutional investors and hedge funds.

Beneficient Company Profile

(Get Free Report)

Beneficient, a technology-enabled financial services company, provides liquidity solutions and related trustee, custody and trust administrative services to participants in the alternative asset industry in the United States. It operates through Ben Liquidity, Ben Custody, and Customer ExAlt Trusts segments.

Further Reading

Insider Buying and Selling by Quarter for Beneficient (NASDAQ:BENF)

Receive News & Ratings for Beneficient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beneficient and related companies with MarketBeat.com's FREE daily email newsletter.